Literature DB >> 7755980

Effects of calprotectin in avridine-induced arthritis.

J G Brun1, G Håland, H J Haga, M K Fagerhol, R Jonsson.   

Abstract

Plasma levels of calprotectin correlate with disease activity and clinical assessments of arthritis in various rheumatic diseases, and high levels have been demonstrated in the synovial fluid of patients with rheumatoid arthritis. However, the role of calprotectin in rheumatic inflammation is unclear. The purpose of the present study was to investigate potential intra-articular effects of calprotectin. Calprotectin was injected into joints of healthy male Lewis rats and into joints of rats in the latency period before onset of avridine-induced arthritis. In addition, a group of animals had IgG antibodies to rat calprotectin injected into joints before onset of avridine-induced arthritis. Injection of 0.2 or 10 micrograms calprotectin into the ankles of healthy male Lewis rats resulted in histologically minor and reversible inflammatory changes, but without any circulating antibodies to calprotectin. Furthermore, animals with 40 micrograms calprotectin injected into ankles before the expected onset of avridine-induced arthritis had lower scores for cellular infiltration than were seen in control joints. This difference did not quite reach statistical significance in the two-sided test used. However, the induced arthritis increased in joints injected with IgG antibodies to calprotectin. These findings may indicate that increased local concentrations of calprotectin are partially protective against avridine-induced arthritis. In contrast, reduced local concentrations appear to exacerbate the severity of arthritis. Calprotectin may thus be involved in the regulation of inflammatory processes in joints.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7755980     DOI: 10.1111/j.1699-0463.1995.tb01100.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  6 in total

Review 1.  Functional and clinical aspects of the myelomonocyte protein calprotectin.

Authors:  B Johne; M K Fagerhol; T Lyberg; H Prydz; P Brandtzaeg; C F Naess-Andresen; I Dale
Journal:  Mol Pathol       Date:  1997-06

2.  The down regulation of neutrophil oxidative metabolism by S100A8 and S100A9: implication of the protease-activated receptor-2.

Authors:  Herve Y Sroussi; Yu Lu; Dana Villines; Ying Sun
Journal:  Mol Immunol       Date:  2011-12-26       Impact factor: 4.407

3.  The C-terminus of murine S100A9 protein inhibits hyperalgesia induced by the agonist peptide of protease-activated receptor 2 (PAR2).

Authors:  C S Dale; N Cenac; L R G Britto; M A Juliano; L Juliano; N Vergnolle; R Giorgi
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

4.  Neutrophilic cell-free exudate induces antinociception mediate by the protein S100A9.

Authors:  Rosana L Pagano; Mario Mariano; Renata Giorgi
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

5.  Neutrophils and the calcium-binding protein MRP-14 mediate carrageenan-induced antinociception in mice.

Authors:  Rosana L Pagano; Maria Angela Amorim Dias; Camila S Dale; Renata Giorgi
Journal:  Mediators Inflamm       Date:  2002-08       Impact factor: 4.711

Review 6.  Resolution of Inflammation: What Controls Its Onset?

Authors:  Michelle A Sugimoto; Lirlândia P Sousa; Vanessa Pinho; Mauro Perretti; Mauro M Teixeira
Journal:  Front Immunol       Date:  2016-04-26       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.